Zhiru Gao Yinghui Xu Jianjiao Zu Xu Wang Chao Sun Shi Qiu Ye Guo Kewei Ma
10.3389/fimmu.2022.946829
Front Immunol
2022 Aug 16;13:946829.
ae camrelizumab nsclc pd-1 adverse event non-small-cell lung cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/36052082/
Autoimmune Diseases Carcinoma, Non-Small-Cell Lung / complications Carcinoma, Non-Small-Cell Lung / drug therapy Lung Neoplasms / complications Lung Neoplasms / drug therapy Vitiligo / complications
Autoimmune Diseases Carcinoma, Non-Small-Cell Lung / complications Carcinoma, Non-Small-Cell Lung / drug therapy Lung Neoplasms / complications Lung Neoplasms / drug therapy Vitiligo / complications Case Reports Cell Death Humans
PMC9424493
36052082
The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
2022